Compare TG Therapeutics Inc (TGTX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Waste Management, Inc. — how do they compare? TG Therapeutics Inc trades at $55.11 (market cap $8.16B), while Waste Management, Inc. trades at $208.63 (market cap $83.98B). The key difference: Waste Management, Inc. is far larger — about 10.3× TG Therapeutics Inc's market cap, and Waste Management, Inc. pays a 1.8% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Waste Management, Inc. for 130 Days on average.
| TGTX | WM | |
|---|---|---|
Market Cap | $8.16B | $83.98B |
Volume | 1,735,121 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $59.06 | $246.51 |
52-Week Low | $26.94 | $196.77 |
Typical Hold Time | 16 Days | 130 Days |
Enterprise Value | $8.37B | $106.78B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Waste Management (WM) trades at $207.71, down 0.59% on the day, with a bullish technical signal despite bearish moving averages. The company reported revenue of $25.20 billion in 2025, with net income of $2.71 billion and a net margin of 10.74%. Recent earnings show mixed results, with a miss in Q4 2025 but beats in Q1 and Q2 2026. Analyst consensus is strongly positive with 54.29% buy ratings and no sell recommendations.
WM's outlook remains favorable due to steady revenue growth, strong cash flow, and a resilient business model. Key risks include elevated debt levels and competitive pressures. The stock offers a reliable dividend, with the next payment of $0.95 scheduled for September 25, 2026. Investors should weigh solid fundamentals against debt concerns for long-term holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
